Business Context and Reporting Period
This Form 8-K is a current report filed by Anteris Technologies Global Corp. on March 31, 2025. The company, incorporated in Delaware and listed on the Nasdaq Global Market under the symbol AVR, is classified as an emerging growth company. The report primarily addresses a significant clinical milestone achieved by the company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific event rather than a periodic financial statement (such as a 10-K or 10-Q).
Material Changes and Events
- Clinical Milestone: On March 31, 2025, the Company announced it has treated 100 patients with its DurAVR® Transcatheter Heart Valve (THV).
- Regulatory Disclosure: The announcement was lodged with the Australian Securities Exchange (ASX) and is included as Exhibit 99.1 to this filing under Item 7.01 (Regulation FD Disclosure).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclaimer that the information is furnished and not deemed filed for purposes of Section 18 of the Exchange Act unless specifically referenced in a subsequent filing.
Key Facts for Investor Verification
- Verify the details of the 100-patient milestone in the attached ASX announcement (Exhibit 99.1).
- Confirm the clinical status and regulatory pathway of the DurAVR® THV following this milestone.
- Review upcoming periodic reports (10-Q or 10-K) for financial data, as this 8-K contains no financial metrics.